SAN FRANCISCO, April 23, 2022 /PRNewswire/ — Nektar Therapeutics NKTR announced that collaborators from the Cairo Laboratory at New York Medical College today presented data from several preclinical studies demonstrating the potential of NKTR-255 to enhance the anti-tumor activities of different CAR-T therapies in a variety of cancer preclinical models. Presentations include an oral presentation by Wen Luo, Ph.D., assistant professor of pediatrics at NYMC, on in vivo and in vitro efficacy of NKTR-255 combined with anti-MCAM^a CAR^b modified Natural Killer (NK) cells in several tumor models, and a poster presentation by Yaya Chu, Ph.D., assistant professor of pediatrics at NYMC, presenting studies of NKTR-255 in combination with ex vivo expanded anti-CD19 CAR NK cells and anti-CD20 or anti-CD79 antibodies in models of Burkitt Lymphoma (BL).

“Our research builds on the body of knowledge for the role of an agent which activates the full IL-15 biology pathway in the field of cell therapy,” said Mitchell S. Cairo, M.D., director of the Cairo Laboratory, chief of pediatric hematology, oncology and stem cell transplantation, director of the Children and Adolescent Cancer and Blood Diseases Center, associate chairman of the Department of Pediatrics and professor of pediatrics, medicine, pathology, microbiology and immunology and cell biology and anatomy at NYMC. “My lab’s findings show that NKTR-255’s ability to expand and proliferate NK cells resulted in the enhancement of the efficacy of two different CAR therapies in our preclinical models.”

The oral presentation will be virtually live streamed on Saturday April 23^rd, 2022 at 3:00 PM MT and is accessible through the meeting organizer’s website at https://www.astct.org/attend/tandem-meetings. These presentations are available for download at http://www.nektar.com/science/scientific-posters.

Key details and takeaways from the two collaborator presentations include:

Abstract 27: “Targeting Ewing sarcoma, Osteosarcoma and…